US Oncology Receives CEO Gold Standard(TM) Certification
"We are excited about this significant accreditation," said BruceBroussard, president and chief executive officer of US Oncology. "Thecertification illustrates our continued commitment to enhancing access toadvanced cancer care for our employees and their families through innovativeservices that increase effectiveness, efficiency and safety."
The CEO Roundtable on Cancer -- an outgrowth of C-Change, a non-profitfoundation of public and private cancer fighting organizations -- created theCEO Cancer Gold Standard. The CEO Cancer Gold Standard calls for companies toevaluate their benefits and culture and take extensive, concrete actions infive key areas of health and wellness to fight cancer in the workplace. Toearn Gold Standard accreditation, a company must establish programs to reducecancer risk by discouraging tobacco use and encouraging physical activity,healthy diet and nutrition; detect cancer at its earliest stages; and provideaccess to quality care, including the availability of clinical trials.
The most recent President's Cancer Panel report, "Promoting HealthyLifestyles: Policy, Program, and Personal Recommendations for Reducing CancerRisk," identified the CEO Cancer Gold Standard as an initiative that ishelping reverse negative, unhealthy lifestyle trends and creating hope in thefight against cancer for America's workers and their families.
"As US Oncology's member of the CEO Roundtable on Cancer, I am delightedto work with both organizations to help US Oncology and other company leadersensure their employees have the tools they need to fight cancer," said LloydK. Everson M.D., vice chairman of US Oncology and one of its founders. Dr.Everson was appointed by President Bush to the National Cancer Advisory Boardin 2006 and was selected to participate in a roundtable discussion hosted bythe President's Cancer Panel.
US Oncology is the twenty-sixth organization to achieve Gold Standardaccreditation. Joining US Oncology in this workplace-based efforts toeliminate cancer as public health threat are: American Cancer Society,American Legacy Foundation, AstraZeneca, C-Change, Duke Medicine, Edelman,Enzon Pharmaceuticals, GHI, GlaxoSmithKline, Jenner & Block, Johnson &Johnson, The Lance Armstrong Foundation, MD Anderson Cancer Center, H. LeeMoffitt Cancer Center and Research Institute, Novartis, OSI Pharmaceuticals,Pfizer, PhRMA, PPD, Quintiles Transnational, SAS Institute, The University ofNorth Dakota, Valeant Pharmaceuticals, Virtua Health and the Wistar Institute.
About US Oncology
US Oncology, headquartered in Houston, works closely with physicians,manufacturers and payers to identify and deliver innovative services thatenhance patient access to advanced cancer care. US Oncology supports one ofthe nation's foremost cancer treatment and research networks, accelerating theavailability and use of evidence-based medicine and shared best practices.
US Oncology's expertise in supporting every aspect of the cancer caredelivery system -- from drug development to treatment and outcomesmeasurement, enables the company to help increase the efficiency and safety ofcancer care. According to the company's last quarterly earnings report, USOncology is affiliated with 1,220 physicians operating in 480 locations,including 92 radiation oncology facilities in 39 states. For more information,visit the company's Web site, http://www.usoncology.com.
About the CEO Roundtable on Cancer
The CEO Roundtable on Cancer was founded in 2001, as an outgrowth ofC-Change, when former President George H.W. Bush challenged a group ofexecutives to "do something bold and venturesome about cancer within your owncorporate families."
The CEO Roundtable then responded with the CEO Cancer Gold Standard,encouraging its widespread adoption in workplaces across the country. For moreinformation on the CEO Cancer Gold Standard(TM) and the accreditation process,please visit http://www.CancerGoldStandard.org.
SOURCE US Oncology, Inc.
You May Also Like